Related Experiment Video
Updated: May 15, 2026
10:58
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
HIV-1 Vaccine Trials: Evolving Concepts and Designs
Missa P Sanou1, Anne S De Groot, Michael Murphey-Corb
1Department of Infectious Diseases and Pathology, College of Veterinary Medicine, University of Florida, P.O. Box 110880, Gainesville, FL 32611, USA.
The Open AIDS Journal
|January 5, 2013
Summary
Developing an effective HIV vaccine remains a challenge. This review summarizes T-cell epitope vaccine strategies and proposes a novel approach using SIV/FIV antigens for robust HIV control.
Area of Science:
- Vaccinology
- Immunology
- Virology
Background:
- An effective prophylactic HIV-1 vaccine is crucial for eradicating the HIV/AIDS pandemic.
- Previous HIV vaccine trials, including the RV144 prime-boost trial, have shown only moderate success, highlighting the need for robust immune responses.
- Both humoral and cellular immunity are important for controlling HIV replication, with T-cell responses being particularly significant.
Purpose of the Study:
- To review the concepts and outcomes of T-cell epitope-based HIV vaccines.
- To discuss strategies for enhancing the immunogenicity of cell-mediated approaches.
- To introduce a novel vaccine strategy utilizing conserved T-cell epitopes from SIV and FIV antigens.
Main Methods:
- Review of existing literature on T-cell epitope-based vaccine concepts and clinical trial outcomes.
- Analysis of strategies to improve the immunogenicity of cell-mediated immunity.
- Identification of conserved HIV-specific T-cell epitopes within SIV and FIV antigens.
Main Results:
- Phase I/IIa trials of multi-epitope HIV vaccines using conserved CTL epitopes have not consistently induced robust anti-HIV CTL responses.
- Efforts to enhance the immunogenicity of cell-mediated vaccine approaches are ongoing.
- A novel approach involves using SIV and FIV antigens containing conserved HIV-specific T-cell epitopes.
Conclusions:
- Designing an effective HIV vaccine requires robust cellular and humoral immune responses.
- Current T-cell epitope-based vaccines face challenges in inducing consistent and strong CTL responses.
- A novel strategy using SIV/FIV antigens offers a potential alternative for developing a broadly protective HIV vaccine against diverse global isolates.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:20Study Designs in Epidemiology
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...